Jump to content
Sign in to follow this  
Christine

Targeted Agent Shows Dramatic Results in Lung Cancer Subset

Recommended Posts

http://www.curetoday.com/index.cfm/fuse ... le_id/1505

BY ELIZABETH WHITTINGTON

An investigational drug, Crizotinib (PF-02341066), which targets a newly discovered gene mutation in lung tumors, showed dramatic results in a small phase 1 clinical trial of metastatic non-small cell lung cancer patients. Of the 82 patients evaluated in the trial, almost 87 percent responded to the treatment, with responses lasting from 1 to 15 months. Patients are still being followed, but the probability of the disease not progressing by the six-month mark was 72 percent, and 77 percent are still on therapy.

Researchers were surprised to see such a positive response to the single-agent treatment, especially because most patients had progressed on several different regimens. Crizotinib was also well tolerated with about half the patients experiencing only mild side effects, including diarrhea and vomiting. ALK-positive lung tumors, which make up about 4 percent of lung cancers, tend to be adenocarcinomas and are found in never smokers and younger patients. Researchers are planning two follow-up trials for lung cancer patients who test positive for ALK and have been previously treated.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

×
×
  • Create New...